310443-45-9

Upstream product

• 310442-94-5 ethyl 4-chloro-5-ethylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 
• 23856-21-5 1-benzyl-1H-indazol-5-ylamine 
• 310436-60-3 5-Ethylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one-6-carboxylic Acid Ethyl Ester 
• 869066-98-8 1-amino-3-ethyl-1H-pyrrole-2,4-dicarboxylic acid diethyl ester 
• 52921-22-9 3-ethyl-1H-pyrrole-2,4-dicarboxylic acid diethyl ester 
• 2999-46-4 Ethyl isocyanoacetate 

Downstream Products

• 310443-46-0 5-Ethyl-4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester 
• 888709-57-7 [4-(1-benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-acetonitrile 
• 888709-52-2 4-(1-benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazine-6-carbaldehyde 
• 310444-99-6 5-Ethyl-4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic Acid 

Relevant academic research and scientific papers

Pyrrolotriazine inhibitors of kinases

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

New dual inhibitors of EGFR and HER2 protein tyrosine kinases

A novel series of dual EGFR and HER2 inhibitors based on the pyrrolo[2,1-f][1,2,4]triazine nucleus is described. A general route toward their synthesis, which enables functionalization at multiple sites, has been developed. Biological evaluation in enzyma